沙利度胺联合强的松治疗溃疡性结肠炎的临床疗效及对患者肠屏障功能、炎症指标的影响

doi:10.3969/j.issn.1671-7171.2024.08.026

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1228 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨沙利度胺联合强的松治疗溃疡性结肠炎(UC)的临床疗效及对患者肠屏障功能、炎症指标的影响。【方法】回顾性分析2021年4月至2023年3月本院收治的92例UC患者的临床资料,根据治疗方案不同将其分为对照组(在常规治疗的基础上给予强的松治疗)和观察组(在对照组的基础上给予沙利度胺治疗),每组46例。治疗8周后,比较两组疗效、病情相关评分[梅奥内镜(Mayo)评分、UC内镜严重程度指数(UCEIS)评分]、肠屏障功能相关指标[二胺氧化酶(DAO)、血乳酸(LAC)、细菌脂多糖(LPS)、D乳酸(D-LA)]、炎症相关指标[Toll样受体4(TLR-4)、核因子κB(NF-κB)、可溶性晚期糖化终末产物受体(sRAGE)]及不良反应发生率。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组Mayo评分、UCEIS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组血清DAO、LAC、LPS、D-LA水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组NF-κB、TLR-4、sRAGE低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】沙利度胺联合强的松治疗UC效果较好,可减轻肠黏膜炎症,改善肠屏障功能,且安全性较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姜瑞红
	郭南南
	王海丽
	郑璐

关键词 ：结肠炎,溃疡性/药物疗法, 沙利度胺/治疗应用, 泼尼松/治疗应用

Abstract：【Objective】To investigate the clinical efficacy of thalidomide combined with prednisone in the treatment of ulcerative colitis (UC) and its effects on intestinal barrier function and inflammatory indicators in patients.【Methods】A retrospective analysis was conducted on the clinical data of 92 UC patients admitted to our hospital l from April 2021 to March 2023. According to the treatment plan, they were divided into the control group (treated with prednisone in addition to conventional treatment) and the observation group (treated with thalidomide in addition to the control group), with 46 patients in each group. After 8 weeks of treatment, the efficacy, disease-related scores (Mayo endoscopic score, UC endoscopic severity index (UCEIS) score), intestinal barrier function related indicators [diamine oxidase (DAO), blood lactate (LAC), bacterial lipopolysaccharide (LPS), D-lactate (D-LA)], inflammation related indicators [Toll like receptor 4 (TLR-4), nuclear factor kappa B (NF-κB), soluble late glycation end product receptor (sRAGE)], and adverse reactions were compared between the two groups.【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the Mayo score and UCEIS score of both groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05); The levels of serum DAO, LAC, LPS, and D-LA in both groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05); The levels of NF-κB, TLR-4, and sRAGE in both groups were lower than before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the total effective rate of adverse reactions between the two groups (P>0.05).【Conclusion】The combination of thalidomide and prednisone has a good therapeutic effect on UC, which can reduce intestinal mucosal inflammation, improve intestinal barrier function, and is relatively safe.

Key words： Colitis, Ulcerative/DT Thalidomide/TU Prednisone/TU

收稿日期: 2023-09-11

中图分类号:

R574.62

引用本文:

姜瑞红, 郭南南, 王海丽, 郑璐. 沙利度胺联合强的松治疗溃疡性结肠炎的临床疗效及对患者肠屏障功能、炎症指标的影响[J]. 医学临床研究, 2024, 41(8): 1209-1211.
JIANG Ruihong, GUO Nannan, WANG Haili, et al. Clinical Efficacy of Thalidomide Combined with Prednisone in the Treatment of Ulcerative Colitis and its Impact on Intestinal Barrier Function and Inflammatory Indicators in Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1209-1211.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.08.026 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I8/1209